Trial reportRadiation oncology (London, England)2026
Adjuvant stereotactic pancreatic radiotherapy (SPARTA trial): interim safety analysis of an ongoing phase II single center prospective study.
Trial report in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05043857 (Stereotactic PAncreatic RadioTherapy Adjuvant Therapy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Stereotactic PAncreatic RadioTherapy Adjuvant Therapy (SPARTA): Phase II Trial.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis interim safety/toxicity analysis aims to assess toxicity of adjuvant stereotactic body radiation therapy (SBRT) after surgery of pancreatic cancer (PC) with high risk features across an ongoing prospective phase II trial, allowing better integration of chemotherapy and surgery.
methodsThe study started in 2021 and this paper represents an interim safety analysis. Enrollment will last 36 months, followed by 12 months of follow-up for a duration of 4 years and 50 patients. Inclusion criteria are: pT1-T4 adenocarcinoma with or without positive resection margin and/or N1 at lymphadenectomy. Chemotherapy can be administered in neoadjuvant and adjuvant setting. The primary endpoint is local relapse. The secondary endpoints are disease-free survival, overall survival, patterns of failure, acute and late toxicity. Radiation dose is 40 Gy in 5 fractions. Toxicities are recorded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0. The study protocol was approved by the institutional research ethics committee on May 18th 2021 and registered on ClinicalTrials.gov (NCT05043857).
resultsThis preliminary analysis was focused on 50 patients. The median follow-up at the time of the analyses was 16.5 months (range 3-35). Neoadjuvant chemotherapy was administered to 23 patients (46%) and 30 (60%) received adjuvant chemotherapy. No patients experienced ≥ G3 toxicity. The most frequent toxicities during SBRT were: nausea (G1, 18%; G2, 8%), asthenia (G1, 10%), abdominal pain (G1, 12%; G2, 2%) and diarrhea (G1, 6%; G2, 2%). After 3 and 6 months abdominal pain (16%) and diarrhea (12%) remained the most G1-G2 toxicities. At 6 and 12 months, we observed two cases of G2 malabsorption. At 1 year, we recorded G2 abdominal pain (4%) and G1 diarrhea (4%).
conclusionsIn this series, adjuvant SBRT in PC was associated with acceptable tolerability with no ≥G3 toxicity. A longer follow-up is needed to fully characterize late toxicity. The final results are awaited to confirm the safety and efficacy of SBRT as a new therapeutic option for patients with resected PC.
trial registrationThe study protocol was approved by the institutional research ethics committee (Comitato Etico Indipendente IRCCS Humanitas Research Hospital) on May 18th 2021 and registered on ClinicalTrials.gov (NCT05043857) on September 14th 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.